Novozymes A/S ADR(NVZMY)- OTCPK - Current
  • Thu, May 19, 11:48 AM
    • A Monsanto (MON +4.9%) takeover by Bayer is considered "relatively unlikely" by Jefferies analyst Laurence Alexander, as he expects MON to object to the offer given its conviction in its R&D pipeline and longer-term competitive advantages.
    • Alexander thinks shares of Syngenta (SYT -0.5%) and DuPont (DD -0.7%) could be pressured as regulatory scrutiny likely would intensify if MON gets acquired, and BASF (OTCQX:BASFY -1.4%) could fall on investor concerns of a potential counter-bid.
    • But the analyst sees a potential MON takeover as positive for shares of Novozymes (OTCPK:NVZMY -0.1%) and FMC Corp. (FMC -0.7%), as "a further roll-up of 'specialty generic' agrichemical assets could entice capital, and FMC would be a plausible anchor for such an attempt."
    • Jefferies rates MON as a Hold with a $95 price target.
    • Now read Bayer investor "deeply concerned" about move for Monsanto
    | Thu, May 19, 11:48 AM | 8 Comments
Company Description
Novozymes is the biotech-based world leader in enzymes and microorganisms. With more than 100 types of enzymes and microorganisms and not less than 700 different products Novozymes has the largest product portfolio in the world. <br />In more than 40 different industries and 130 countries, our... More
Industry: Chemicals - Major Diversified
Country: Denmark